2010/09/21

Armanor

Composition, structure and packing

Tablets, coated in white, oblong, with notches on both sides.

1 tab. almitrina bismezilat 50 mg.

Excipients: corn starch, corn starch, gelled, lactose monohydrate, sodium lauryl sulfate, titanium dioxide, macrogol 6000, povidone, magnesium stearate, talc, white beeswax, glycerol, gipromelloza.

Clinico-pharmacological group: Respiratory analeptic.

Pharmacological action

Peripherals respiratory analeptic. Due to stimulation of peripheral chemoreceptors located in the aorta and carotid arteries, the leveling of ventilation-perfusion ratio, ie increase in oxygen pressure in the blood and decrease carbon dioxide tension (increase in SaO2 and PaO2, decrease PaCO2). These effects combined with the improvement of alveolar ventilation, observed during long-term use of the drug, which contributes to a general improvement in gas exchange function.

In applying the drug in doses of 50-100 mg / day observed effects do not depend on any change of ventilation in general, at that point: the absence of any change of indicators defined in the standard functional tests (vital capacity, respiratory rate, O2 consumption), reduction hypoxemia after taking into Armanora in patients with acute decompensation of respiratory function, located on the prolonged mechanical ventilation.

Pharmacokinetics

Absorption

When administered almitrin rapidly absorbed, Cmax in plasma obtained after 3 h after administration.

Distribution

The degree of binding to proteins in blood almitrina high - over 99%. Metabolism is mainly metabolized in the liver.

Withdrawal

Withdrawal of the drug occurs mainly in the faeces, to a lesser extent - in the urine in the form of inactive metabolites. After receiving a single T1 / 2 of 40-80 h, when re-admission - 30 days.

Statement
respiratory failure with hypoxemia with chronic obstructive pulmonary disease (COPD).

Dosage regimen

The drug is intended only for the treatment of adults. Assign inside of 1-2 tab. / day (50-100 mg / day) in 2 divided doses during the main meal. For a single ingestion Armanora in doses exceeding 100 mg may be transient moderate increase in overall ventilation, which can cause poor tolerance to the drug. Patients weighing 50 kg should be administered for 1 tab. / day.

After an initial period of treatment for 3 months at a dose of 50-100 mg switching to maintenance therapy on the scheme: 1 month break - 2 months of treatment.

If necessary, may require dosage adjustment based on patient weight, tolerance to the drug and the severity of the disorder of gas exchange. Due to the fact that almitrin not displayed by the kidneys, patients with renal insufficiency does not require correction of dosing regimen.

Side effect
On the part of metabolism: rarely - weight loss.
From the side of the central nervous system and peripheral nervous system: rarely - sleep disturbance (insomnia), sleepiness, agitation, anxiety, dizziness, prolonged use (over 1 year and over) - peripheral neuropathy with paresthesias of the lower extremities.
On the part of the digestive system: rarely - nausea, heartburn, feeling of heaviness in the epigastrium, indigestion, disorders of the chair.
Since the cardiovascular system: rarely - heartbeat.
On the part of the respiratory system: rarely - a subjective feeling of conscious breathing movements.

Contraindications
severe liver disease;
peripheral neuropathy or peripheral neuropathy cases in history;
Pregnancy
breastfeeding;
Hypersensitivity to the drug.

Pregnancy and lactation

Contraindicated during pregnancy and during breastfeeding.

Application for violations of liver function

If you have severe liver disease in the case of the need for drug therapy Armanor requires careful monitoring of clinical and laboratory parameters. The drug is contraindicated in hepatic failure.

Application for violations of renal function

Due to the fact that almitrin not displayed by the kidneys, patients with renal insufficiency does not require correction of dosing regimen.

Cautions

Armanor can be assigned in conjunction with oxygen therapy. Armanor should not be taken with other medications containing almitrin. Dosage regimen and treatment should be reviewed every 6 months. Therapeutic drug Armanor should be terminated in the following cases:
with a decrease in body weight by more than 5% of the original;
in the presence of sustained lower extremity paresthesias (sensation of tingling, numbness).

If you have severe liver disease in the case of the need for drug therapy Armanor requires careful monitoring of clinical and laboratory parameters. In connection with the presence of lactose drug is not recommended for patients taking the drug with congenital galactosemia, glucose and galactose malabsorption syndrome and lactase deficiency.

Use in Pediatrics

Due to the lack of sufficient clinical data to use the drug Armanor patients under the age of 18 years is not recommended.

Overdose

There have been no cases of overdose.

Symptoms: When you receive a random almitrina in excessive doses may cause hypocapnia with the development of respiratory alkalosis.

Treatment: symptomatic therapy under the control of lung function, heart and blood gases.

Drug Interactions

Armanor should not be taken with other medications containing almitrin.

Terms and Conditions of storage

Special storage conditions required. Keep out of reach of children. Shelf life - 4 years.